Evidence map›Paper›PMID 33973628›Full record

ArticleBioscience reports2021

Potential role for pyruvate kinase M2 in the regulation of murine cardiac glycolytic flux during in vivo chronic hypoxia.

Michal K Handzlik, David J Tooth, Dumitru Constantin-Teodosiu, Paul L Greenhaff, Mark A Cole

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Role of Pyruvate Kinase M2 (PKM2) in Cardiovascular Diseases.Journal of cardiovascular translational research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michal K HandzlikSchool of Life Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham, U.K.ORCID 0000-0002-4653-1902
David J ToothSchool of Life Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham, U.K.
Dumitru Constantin-TeodosiuSchool of Life Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham, U.K.
Paul L GreenhaffSchool of Life Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham, U.K.
Mark A ColeSchool of Life Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham, U.K.ORCID 0000-0002-0727-7833
Queen's Medical Centre · GBArthritis UK · GB

Funding

Biotechnology and Biological Sciences Research Council BB/F016956/1
6 · The paper itself

Abstract

Carbohydrate metabolism in heart failure shares similarities to that following hypoxic exposure, and is thought to maintain energy homoeostasis in the face of reduced O2 availability. As part of these in vivo adaptations during sustained hypoxia, the heart up-regulates and maintains a high glycolytic flux, but the underlying mechanism is still elusive. We followed the cardiac glycolytic responses to a chronic hypoxic (CH) intervention using [5-3H]-glucose labelling in combination with detailed and extensive enzymatic and metabolomic approaches to provide evidence of the underlying mechanism that allows heart survivability. Following 3 weeks of in vivo hypoxia (11% oxygen), murine hearts were isolated and perfused in a retrograde mode with function measured via an intraventricular balloon and glycolytic flux quantified using [5-3H]-glucose labelling. At the end of perfusion, hearts were flash-frozen and central carbon intermediates determined via liquid chromatography tandem mass spectrometry (LC-MS/MS). The maximal activity of glycolytic enzymes considered rate-limiting was assessed enzymatically, and protein abundance was determined using Western blotting. Relative to normoxic hearts, CH increased ex vivo cardiac glycolytic flux 1.7-fold with no effect on cardiac function. CH up-regulated cardiac pyruvate kinase (PK) flux 3.1-fold and cardiac pyruvate kinase muscle isoenzyme M2 (PKM2) protein content 1.4-fold compared with normoxic hearts. CH also augmented cardiac pentose phosphate pathway (PPP) flux, reflected by higher ribose-5-phosphate (R5P) content. These findings support an increase in the covalent (protein expression) and allosteric (flux) control of PKM2 as being central to the sustained up-regulation of the glycolytic flux in the chronically hypoxic heart.

Indexed as

GlycolysisAllosteric RegulationAnimalsChronic DiseaseDisease Models, AnimalHypoxiaIsolated Heart PreparationMaleMetabolomeMiceMyocytes, CardiacPentose Phosphate PathwayPyruvate KinaseRibosemonophosphatesSignal TransductionPkm protein, mousePyruvate Kinaseribose-5-phosphateRibosemonophosphateshypoxiamyocardiumpyruvate kinase M2

Identifiers

PMID33973628
PMCPMC8173528
OpenAlexW3162074554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.